Chris Lange

Chris Lange is an analyst for 24/7 Wall St., based in Houston. He has covered financial markets over the past five years with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and has helped start a small business.

Lastest Stories by Chris Lange

Novavax and Regeneron Pharmaceuticals each made solid progress on Tuesday after each company received a sizable capital injection from the U.S. government’s Operation Warp Speed program.
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
24/7 Wall St. has put together a list of special purpose acquisition company stocks and blank check stocks that could win big this year, and these aren’t just the ones involved in sports betting.
24/7 Wall St. offers a preview of what to expect from some of the most anticipated quarterly results due this week.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Insurance company Lemonade entered the market with a bang on Thursday.
Francesca’s shares more than doubled on Thursday after the company announced the development of its first mobile e-commerce application.
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
A lot of Apple stock’s recent momentum has been due to the excitement around the upcoming iPhone 12 and 5G. Is there a wave of new purchases of smartphones, personal computers and tablets coming...
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
T2 Biosystems solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
FedEx reported fiscal fourth-quarter financial results after markets closed Tuesday. The firm reported $2.53 in earnings per share (EPS) and $17.4 billion in revenue, compared with consensus...
Zynerba Pharmaceuticals shares were practically halved on Tuesday on news that its cannabis-based gel did not see statistically significant results from its most recent study.
OptiNose shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Alterity Therapeutics says it has received an update from the FDA regarding its Parkinson’s treatment. That made shareholders happy.